Long-Acting Oral Weekly Risperidone (LYN-005): Translating Pharmacokinetic Equivalence to Clinical Opportunity in Schizophrenia

Highlights

• LYN-005, a novel long-acting oral risperidone, achieved pharmacokinetic equivalence to daily immediate-release risperidone at steady-state.
• Sustained therapeutic plasma concentrations were observed with weekly dosing, supporting its potential to mitigate adherence challenges in schizophrenia.
• Safety profile was consistent with established risperidone use, with gastrointestinal adverse events most common and no unexpected safety signals.
• The weekly oral formulation may address a critical gap for patients preferring oral therapy but struggling with daily adherence.

Study Background and Disease Burden